Bortezomib-Based Chemotherapy in Multiple Myeloma Patients Without Comorbid Cardiovascular Disease Shows No Cardiotoxicity

ConclusionWe did not observe cardiotoxicity from bortezomib-based chemotherapy despite very intensive evaluation with multiple modalities. There was neither cumulative nor transient alterations in our metrics, suggesting that bortezomib is safe from a cardiovascular standpoint in patients free of cardiovascular disease.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research